NLS Pharmaceutics Offers Preclinical Hope for Parkinson’s Disease Treatment
Shares in Swiss biopharmaceutical company, NLS Pharmaceutics (Nasdaq: NLSP), soared more than 50% in trading after the company announced positive preclinical results from multiple in vitro studies of three compounds, demonstrating their potential to advance the treatment of Parkinson’s Disease (PD). In NLS’ studies, the compounds showed positive effects on neurite outgrowth, a critical parameter of neuronal health and regeneration.
Alex Zwyer, Chief Executive Officer of NLS, said, “These in vitro results obtained from various Aexon Labs preclinical compounds, discovered through our next-generation non-sulfonamide dual orexin agonist (DOXA) platform, show promising insights to help us further the development of potentially differentiated and more effective treatments for patients living with PD.”
NLS’s compounds AEX-23, AEX-19 and AEX-24 demonstrated pronounced action that make them potential therapeutic candidates to improve neuronal connectivity and resilience, offer neuroprotective benefits, and have promising therapeutic impact in PD.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
